FOLH1 and cancer: Preclinical data support CDCP1 as a target for delivery of imaging and cytotoxic payloads for detection and personalized treatment of cancers that display elevated levels of this receptor and currently have limited treatment options for advanced disease including ovarian clear cell carcinoma, high-grade serous ovarian carcinoma, pancreatic ductal adenocarcinoma (PDAC), colorectal cancer and castration resistant prostate cancer including PSMA null disease 12-16.